AIM ImmunoTech Inc.

LSE:0A4Y Stock Report

Market Cap: US$14.3m

AIM ImmunoTech Valuation

Is 0A4Y undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0A4Y when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0A4Y's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0A4Y's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0A4Y?

Key metric: As 0A4Y barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0A4Y. This is calculated by dividing 0A4Y's market cap by their current book value.
What is 0A4Y's PB Ratio?
PB Ratio4.9x
BookUS$2.91m
Market CapUS$14.33m

Price to Book Ratio vs Peers

How does 0A4Y's PB Ratio compare to its peers?

The above table shows the PB ratio for 0A4Y vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.3x
PBX ProBiotix Health
6.2xn/aUK£7.9m
SNG Synairgen
1x50.2%UK£9.6m
VRCI Verici Dx
1xn/aUK£8.2m
CIZ Cizzle Biotechnology Holdings
9xn/aUK£7.1m
0A4Y AIM ImmunoTech
4.9x-0.3%US$14.3m

Price-To-Book vs Peers: 0A4Y is expensive based on its Price-To-Book Ratio (4.9x) compared to the peer average (4.3x).

Price to Book Ratio vs Industry

How does 0A4Y's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
BDRX Biodexa Pharmaceuticals
0.5xn/aUS$4.42m
LLAI LungLife AI
0.4x101.0%US$3.46m
VAL ValiRx
0.6xn/aUS$2.78m
No more companies available in this PB range
0A4Y 4.9xIndustry Avg. 2.8xNo. of Companies7PB02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0A4Y is expensive based on its Price-To-Book Ratio (4.9x) compared to the UK Biotechs industry average (2.9x).

Price to Book Ratio vs Fair Ratio

What is 0A4Y's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0A4Y PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio4.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0A4Y's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0A4Y forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.22
US$3.00
+1,278.0%
66.7%US$5.00US$1.00n/a2
Nov ’25US$0.26
US$3.17
+1,137.0%
52.1%US$5.00US$1.00n/a3
Oct ’25US$0.28
US$3.50
+1,163.1%
35.0%US$5.00US$2.00n/a3
Sep ’25US$0.39
US$3.50
+809.1%
35.0%US$5.00US$2.00n/a3
Aug ’25US$0.36
US$3.58
+895.4%
37.1%US$5.25US$2.00n/a3
Jul ’25US$0.40
US$3.58
+798.2%
37.1%US$5.25US$2.00n/a3
Jun ’25n/a
US$3.58
0%
37.1%US$5.25US$2.00n/a3
May ’25n/a
US$3.50
0%
35.0%US$5.00US$2.00n/a3
Apr ’25US$0.48
US$2.75
+468.8%
27.3%US$3.50US$2.00n/a2
Mar ’25US$0.41
US$3.83
+826.4%
43.0%US$6.00US$2.00n/a3
Feb ’25US$0.42
US$3.83
+813.1%
43.0%US$6.00US$2.00n/a3
Jan ’25US$0.44
US$3.83
+779.2%
43.0%US$6.00US$2.00n/a3
Dec ’24US$0.48
US$3.83
+706.8%
43.0%US$6.00US$2.00n/a3
Nov ’24US$0.43
US$3.83
+791.3%
43.0%US$6.00US$2.00US$0.263
Oct ’24US$0.53
US$3.83
+626.3%
43.0%US$6.00US$2.00US$0.283
Sep ’24US$0.64
US$3.92
+511.0%
44.9%US$6.25US$2.00US$0.393
Aug ’24US$0.61
US$3.92
+542.1%
44.9%US$6.25US$2.00US$0.363
Jul ’24US$0.63
US$3.92
+521.8%
44.9%US$6.25US$2.00US$0.403
Jun ’24US$0.48
US$3.92
+721.1%
44.9%US$6.25US$2.00n/a3
May ’24US$0.49
US$5.33
+979.6%
30.9%US$6.50US$3.00n/a3
Apr ’24US$0.40
US$5.42
+1,254.2%
31.6%US$6.75US$3.00US$0.483
Mar ’24US$0.51
US$5.42
+962.1%
31.6%US$6.75US$3.00US$0.413
Feb ’24n/a
US$5.42
0%
31.6%US$6.75US$3.00US$0.423
Jan ’24n/a
US$5.42
0%
31.6%US$6.75US$3.00US$0.443
Dec ’23n/a
US$5.42
0%
31.6%US$6.75US$3.00US$0.483
Nov ’23n/a
US$5.58
0%
33.2%US$7.25US$3.00US$0.433

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

hVIVO

UK£134.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.20

7D

-16.8%

1Y

2.1%

Formycon

€844.9m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.35

7D

2.8%

1Y

-24.9%

Regeneron Pharmaceuticals

US$81.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$749.80

7D

1.3%

1Y

-7.7%